CliffBio
small molecule

DIVALPROEX SODIUM

DIVALPROEX SODIUM

Loss of exclusivity—loss of exclusivity
CompanyCosette Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameDIVALPROEX SODIUM
Active ingredientDIVALPROEX SODIUM
StrengthEQ 500MG VALPROIC ACID
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2009
Marketing statusDISCN

More from Cosette Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.